Honeywell teams with astrazeneca to develop next-generation respiratory inhalers that use near-zero global warming potential propellant

Charlotte, n.c., feb. 22, 2022 /prnewswire/ -- honeywell (nasdaq: hon) today announced a commercial partnership with astrazeneca (lon: azn) to develop and bring to market next-generation respiratory inhalers that use near-zero global warming potential (gwp) propellants to treat asthma and chronic obstructive pulmonary disease (copd).
HON Ratings Summary
HON Quant Ranking